On Wednesday, after Boston Scientific (NYSE:BSX) announced the acquisition of Minnesota startup BridgePoint Medical, the startup’s CEO said that he is excited by the prospect of having the company’s technology marketed by Boston Scientific’s sales and marketing operation. Describing Boston Scientific as the “leader” in the interventional cardiology field and the cath lab, Denis Harrington […]
Boston Scientific (NYSE:BSX) announced Wednesday that it is acquiring Minneapolis-based BridgePoint Medical, which has developed minimally invasive technologies to treat complete blockage of the coronary artery or coronary chronic total occlusions. The terms of the transaction, expected to close in the fourth quarter, were not disclosed. BridgePoint Medical’s Coronary Total Occlusion (CTO) system comprises the CrossBoss CTO […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Denis Harrington, who until recently was head of sales for Boston Scientific Corp.'s cardiovascular and CRM business, has left the company to become president and CEO of a Twin Cities startup called BridgePoint Medical Inc.
BridgePoint Medical Inc. has raised $9.1 million from the sale of equity. The company based in Plymouth, Minnesota, is developing balloon catheter system to treat chronic coronary and peripheral total occlusions, a condition in which clots frequently clog blood vessels.
BridgePoint Medical Inc. has raised $1 million from the sale of debt and stock warrants, according to documents filed with the Securities and Exchange Commission. The company, based in Plymouth, Minnesota, is developing balloon catheter system to treat chronic coronary and peripheral total occlusions, a condition in which clots frequently clog blood vessels. Last year, […]
Ground was supposed to have been broken in the fourth quarter of 2008, according to Tower Investments. Now, after delays and increasing skepticism from the public, John Pierce, senior vice president at Tower Investments LLC, said that plans have changed.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
The company has developed two interventional catheters that are designed to help cardiologists navigate diseased arteries in order to restore blood flow and place stents.